{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxotere%C2%AE", "query": { "intervention": "Taxotere®" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 143, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxotere%C2%AE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T14:38:41.943Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00270894", "title": "Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasm" ], "interventions": [ { "name": "epirubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 30, "start_date": "2005-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2012-03-20", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 7, "location_summary": "Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Billings", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00270894" }, { "nct_id": "NCT00084786", "title": "Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00084786" }, { "nct_id": "NCT02131064", "title": "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2014-06-25", "completion_date": "2018-05-29", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 16, "location_summary": "Fullerton, California • Los Angeles, California • San Luis Obispo, California + 13 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02131064" }, { "nct_id": "NCT04854499", "title": "Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 193, "start_date": "2021-09-07", "completion_date": "2024-10-02", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 22, "location_summary": "Chandler, Arizona • Duarte, California • Los Angeles, California + 19 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854499" }, { "nct_id": "NCT00066885", "title": "Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "calcitriol + docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novacea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2003-06", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2007-05-07", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 11, "location_summary": "Berkeley, California • Vallejo, California • Denver, Colorado + 8 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Albany", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066885" }, { "nct_id": "NCT00996333", "title": "Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine, Docetaxel, Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2003-06", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00996333" }, { "nct_id": "NCT00546364", "title": "Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2", "type": "DRUG" }, { "name": "Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2", "type": "DRUG" }, { "name": "Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2008-02", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2016-03-10", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 60, "location_summary": "Tuscaloosa, Alabama • La Jolla, California • Southington, Connecticut + 52 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Southington", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546364" }, { "nct_id": "NCT04527991", "title": "Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Unresectable Urothelial Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 711, "start_date": "2021-01-13", "completion_date": "2025-07-04", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04527991" }, { "nct_id": "NCT04185883", "title": "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Kirsten Rat Sarcoma (KRAS) pG12C Mutation" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "RMC-4630", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" }, { "name": "Carboplatin, pemetrexed, docetaxel, paclitaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "MVASI® (bevacizumab-awwb)", "type": "DRUG" }, { "name": "TNO155", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 1)", "type": "DRUG" }, { "name": "IV Chemotherapy (Regimen 2)", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "AMG 404", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 610, "start_date": "2019-12-17", "completion_date": "2027-12-05", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 55, "location_summary": "Tucson, Arizona • Duarte, California • La Jolla, California + 42 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04185883" }, { "nct_id": "NCT03671044", "title": "A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Nanosomal Docetaxel Lipid Suspension (75 mg/m2)", "type": "DRUG" }, { "name": "Nanosomal Docetaxel Lipid Suspension (100 mg/m2)", "type": "DRUG" }, { "name": "Taxotere® (100 mg/m2)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jina Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 657, "start_date": "2018-07-10", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-09-29T14:38:41.943Z", "location_count": 3, "location_summary": "Columbus, Georgia • Springfield, Missouri • Canton, Ohio", "locations": [ { "city": "Columbus", "state": "Georgia" }, { "city": "Springfield", "state": "Missouri" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03671044" } ] }